Zynerba Pharmaceuticals, Inc.
TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL

Abstract:

The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject